TheraRadar
← Back
Data updated: Mar 29, 2026

AMPHASTAR PHARMS INC

OncologyInfectious DiseaseCardiovascular
Specialty

AMPHASTAR PHARMS INC is a specialty pharmaceutical company focused on Oncology, Infectious Disease, Cardiovascular. Key products include REXTOVY.

1970
Since
14
Drugs
-
Trials
30
Approved (2yr)

Key Drugs

REXTOVY
naloxone hydrochloride
Opioid receptor 3 indications · 2023
BAQSIMI
glucagon
Metabolic
Glucagon receptor 2 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

TERIPARATIDE 2025-12-12
ISOPROTERENOL HYDROCHLORIDE 2025-12-10
NEOSTIGMINE METHYLSULFATE 2025-10-24
Labeling
GLUCAGON 2025-09-15
SUCCINYLCHOLINE CHLORIDE 2025-08-15
Labeling
SUCCINYLCHOLINE CHLORIDE 2025-08-15
Labeling
GLUCAGON 2025-07-30
Labeling
GLUCAGON 2025-07-22
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 35%
0 drugs Phase 3: 3 Phase 1: 2
Infectious Disease 20%
0 drugs Phase 3: 1 Phase 2: 2
Cardiovascular 15%
1 drugs
Respiratory 15%
1 drugs
Metabolic 15%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory